

# THERAPEUTICS FOR WOMEN'S HEALTH: TECHNOLOGIES AND GLOBAL MARKETS



**BIO043F**  
**May 2016**

Dr. Ritu Thakur Dangi  
***Project Analyst***

ISBN: 1-62296-284-2



**BCC Research**  
**49 Walnut Park, Building 2**  
**Wellesley, MA 02481 USA**  
**866-285-7215 (toll-free within the USA),**  
**or (+1) 781-489-7301**  
**[www.bccresearch.com](http://www.bccresearch.com)**  
**[information@bccresearch.com](mailto:information@bccresearch.com)**

## TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY BACKGROUND	2
STUDY GOALS AND OBJECTIVES	3
INTENDED AUDIENCE	4
SCOPE OF THE REPORT	4
METHODOLOGY AND INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	5
RELATED BCC RESEARCH REPORTS	5
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, 2014-2020 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW OF WOMEN'S HEALTH DISORDERS	10
DISEASE OVERVIEW AND DEFINITIONS	10
<i>TABLE 1 GLOBAL GENERAL FEMALE POPULATION VS POPULATION SUFFERING FROM A WOMEN'S DISORDER, THROUGH 2020 (MILLIONS)</i>	11
<i>FIGURE 1 DISTRIBUTION OF GLOBAL POPULATION SUFFERING FROM A WOMEN'S DISORDER BY TYPE, 2015 (% OF TOTAL GENERAL FEMALE POPULATION)</i>	12
HISTORICAL BACKGROUND	12
AGING AND WOMEN'S HEALTH DISORDERS	14
<i>FIGURE 2 FEMALE LIKELIHOOD OF BECOMING PREGNANT VERSUS INFERTILITY AS AGE PROGRESSES, 2015 (%)</i>	14
NEW USE FOR CONTRACEPTIVES	15
WOMEN AND SEXUAL HEALTH	17
FEMALE SEXUAL AROUSAL DISORDER	17
FEMALE ORGASMIC DISORDER	18
VAGINISMUS	19
INFERTILITY AND CANCER	19
CHAPTER 4 MENOPAUSE-RELATED SYMPTOMS AND DISEASES	21
OVERVIEW	21
ETIOLOGY	22
EPIDEMIOLOGY AND ECONOMIC BURDEN	22
<i>TABLE 2 GLOBAL PREVALENCE OF MENOPAUSE-RELATED CONDITIONS BY REGION, THROUGH 2020 (MILLIONS)</i>	22
<i>FIGURE 3 GLOBAL PREVALENCE OF MENOPAUSE-RELATED CONDITIONS BY REGION, 2014-2020 (MILLIONS)</i>	22
<i>FIGURE 4 GLOBAL POPULATION OF FEMALES SUFFERING FROM MENOPAUSE-RELATED CONDITIONS VS THE GENERAL FEMALE POPULATION, 2014-2020 (MILLIONS)</i>	23

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 5 GLOBAL DISTRIBUTION OF FEMALES SUFFERING FROM MENOPAUSE-RELATED CONDITIONS BY REGION, 2015 (% OF GENERAL FEMALE POPULATION)</i>	24
SYMPTOMS OF MENOPAUSE	24
RISK FACTORS FOR EARLY ONSET MENOPAUSE	25
DIAGNOSIS AND TREATMENT	26
DIAGNOSIS OF MENOPAUSE	26
TREATMENT OPTIONS	27
<i>TABLE 3 COMMONLY PRESCRIBED DRUGS USED TO TREAT THE SYMPTOMS OF MENOPAUSE</i>	27
Minivelle (Estradiol)	28
FemSeven (Estradiol)	29
Premarin (Conjugated Estrogens)	29
Prempro (Conjugated Estrogens/Medroxyprogesterone Acetate Tablets)	30
Vagifem (Estradiol Vaginal Tablets)	30
Femring (Estradiol Acetate Vaginal Ring)	30
ISSUES ASSOCIATED WITH HORMONE THERAPY	31
REDUCING THE RISK OF EARLY MENOPAUSE	31
CHAPTER 5 POSTMENOPAUSAL OSTEOPOROSIS	34
DISEASE OVERVIEW	34
HUMAN BONE STRUCTURE	34
EPIDEMIOLOGY AND ECONOMIC BURDEN	35
<i>TABLE 4 GLOBAL PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS BY REGION, THROUGH 2020 (MILLIONS)</i>	35
<i>FIGURE 6 GLOBAL PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS BY REGION, 2014-2020 (MILLIONS)</i>	36
<i>FIGURE 7 GLOBAL POPULATION OF FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS VS THE OVERALL FEMALE POPULATION, 2014-2020 (MILLIONS)</i>	36
<i>FIGURE 8 GLOBAL DISTRIBUTION OF FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS BY GEOGRAPHIC REGION, 2015 (% OF FEMALE POPULATION)</i>	37
DISEASE SYMPTOMS AND RISK FACTORS	38
DISEASE SYMPTOMS	38
Fractures	38
Spinal Deformities	39
Pain	39
RISK FACTORS	39
DIAGNOSIS AND TREATMENT	40
DIAGNOSIS OF POSTMENOPAUSAL OSTEOPOROSIS	40
TREATMENT OPTIONS FOR POSTMENOPAUSAL OSTEOPOROSIS	41
Bisphosphonates	41
Hormone Therapy	42
Selective Estrogen Receptor Modulators (SERMs)	43
Calcitonin	43
Parathyroid Hormone	44
<i>TABLE 5 COMMONLY PRESCRIBED DRUGS USED TO TREAT POSTMENOPAUSAL OSTEOPOROSIS</i>	44
Caltrate (Calcium Carbonate)	45

<b>TOPIC</b>	<b>PAGE NO.</b>
Edirol (Eldecalcitol)	46
Pralia (Denosumab)	46
Protelos (Strontium Ranelate)	46
Miacalcin (Calcitonin Salmon)	46
Fosamax (Alendronate Sodium)	46
Actonel (Risedronate Sodium)	47
Evista (Raloxifene Hydrochloride)	48
Boniva (Ibandronate Sodium)	48
Forteo (Teriparatide (rDNA Origin)) Injection	49
Reclast (Zoledronate)	49
Calcitonin (Calcimar, Miacalcin)	50
Forteo (Teriparatide)	50
Aprala (Bazedoxifene/Conjugated Estrogen)	51
Viviant (Bazedoxifene)	51
REDUCING THE RISK OF OSTEOPOROSIS	51
CHAPTER 6 ENDOMETRIOSIS	54
DISEASE OVERVIEW	54
ETIOLOGY AND PATHOPHYSIOLOGY	55
DISEASE SYMPTOMS AND RISK FACTORS	56
PELVIC PAIN	56
DIFFICULTY BECOMING PREGNANT	56
ENDOMETRIOMAS	57
RISK FACTORS	57
Genetic Factors	57
Delayed Pregnancy	57
Age	57
Dietary Factors	58
STAGES OF ENDOMETRIOSIS	58
EPIDEMIOLOGY AND ECONOMIC BURDEN	59
TABLE 6 PREVALENCE OF ENDOMETRIOSIS BY REGION, THROUGH 2020 (MILLIONS)	59
FIGURE 9 PREVALENCE OF ENDOMETRIOSIS BY REGION, 2014-2020 (MILLIONS)	59
FIGURE 10 GLOBAL ENDOMETRIOSIS POPULATION VS OVERALL FEMALE POPULATION, 2014-2020 (MILLIONS)	60
FIGURE 11 GLOBAL DISTRIBUTION OF ENDOMETRIOSIS POPULATION BY REGION, 2015 (% OF FEMALE POPULATION)	61
DIAGNOSIS AND TREATMENT	62
DIAGNOSIS OF ENDOMETRIOSIS	62
Pelvic Exam	62
Laparoscopy	62
Other Diagnostic Procedures	63
TREATMENT OPTIONS FOR ENDOMETRIOSIS	63
Pharmacological Treatment	64
NSAIDs	64
Hormonal Birth Control Treatments	64
Progestins	65
Gonadotropin Releasing Hormone Agonists	65
TABLE 7 DRUGS COMMONLY USED TO TREAT ENDOMETRIOSIS	66

<b>TOPIC</b>	<b>PAGE NO.</b>
Zoladex	66
Visanne (Dienogest)	67
Lupron Depot (Leuprolide Acetate)	67
Synarel (Nafarelin Acetate)	67
Danazol	67
Visanne	67
Surgery	68
LOWERING THE RISK OF ENDOMETRIOSIS	69
CHAPTER 7 POLYCYSTIC OVARY SYNDROME	71
DISEASE OVERVIEW	71
ETIOLOGY	71
EPIDEMIOLOGY AND ECONOMIC BURDEN	72
TABLE 8 PREVALENCE OF POLYCYSTIC OVARY SYNDROME BY REGION, THROUGH 2020 (MILLIONS)	72
FIGURE 12 PREVALENCE OF POLYCYSTIC OVARY SYNDROME BY REGION, 2014-2020 (MILLIONS)	73
FIGURE 13 GLOBAL POLYCYSTIC OVARY SYNDROME DISEASE POPULATION VS FEMALE POPULATION, 2014-2020 (MILLIONS)	73
FIGURE 14 GLOBAL DISTRIBUTION OF POLYCYSTIC OVARY SYNDROME POPULATION BY REGION, 2015 (% OF FEMALE POPULATION)	74
DISEASE SYMPTOMS AND RISK FACTORS	74
DIAGNOSIS AND TREATMENT	75
DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME	75
Medical History and Physical Examination	75
Pelvic Examination	75
Laboratory Testing	75
Imaging Tests	76
TREATMENT OPTIONS FOR POLYCYSTIC OVARY SYNDROME	76
TABLE 9 COMMONLY PRESCRIBED GENERIC DRUGS FOR THE TREATMENT OF POLYCYSTIC OVARY SYNDROME	77
Medications	79
Clomid (Clomiphene)	79
Vaniqa (Eflornithine)	79
Glucophage (Metformin)	79
Actos (Pioglitazone) and Avandia (Rosiglitazone)	79
Aldactone (Spironolactone)	79
Precose (Acarbose)	80
Apri (Desogestrel/Ethinyl Estradiol)	80
Propecia (Finasteride)	80
Eulexin (Flutamide)	80
Femara (Letrozole)	80
REDUCING THE RISK OF PCOS	80
CHAPTER 8 BREAST CANCER	83
DISEASE OVERVIEW	83
ETIOLOGY AND PATHOPHYSIOLOGY	83
DISEASE SYMPTOMS AND RISK FACTORS	84

<b>TOPIC</b>	<b>PAGE NO.</b>
SYMPTOMS	84
RISK FACTORS	84
TYPES AND STAGES OF BREAST CANCER	85
<i>TABLE 10 TNM CLASSIFICATIONS OF BREAST CANCERS</i>	86
<i>TABLE 11 FIVE-YEAR SURVIVAL RATE BASED ON STAGE OF BREAST CANCER FOR WOMEN IN THE U.S, 2015 (%)</i>	87
EPIDEMIOLOGY AND ECONOMIC BURDEN	87
<i>TABLE 12 PREVALENCE OF BREAST CANCER BY REGION, THROUGH 2020 (MILLIONS)</i>	87
<i>FIGURE 15 PREVALENCE OF BREAST CANCER BY REGION, 2014-2020 (MILLIONS)</i>	88
<i>FIGURE 16 GLOBAL BREAST CANCER POPULATION VS OVERALL FEMALE POPULATION, 2014-2020 (MILLIONS)</i>	88
<i>FIGURE 17 GLOBAL DISTRIBUTION OF BREAST CANCER POPULATION BY REGION, 2015 (% OF FEMALE POPULATION)</i>	89
DIAGNOSIS AND TREATMENT	90
DIAGNOSIS OF BREAST CANCER	90
TREATMENT OPTIONS FOR BREAST CANCER	92
<i>TABLE 13 TYPES OF HORMONE THERAPY FOR BREAST CANCER</i>	93
Cancer Treatment: Local or Systemic	93
<i>TABLE 14 DRUGS COMMONLY USED TO TREAT BREAST CANCER</i>	94
Medications	95
Alkeran (Melphalan)	95
Taxol (Paclitaxel)	96
Methotrexate Sodium	96
Herceptin (Trastuzumab)	96
Ellence (Epirubicin Hydrochloride)	96
Aromasin (Exemestane)	97
Adrucil (Fluorouracil)	97
Femara (Letrozole)	97
Velban (Vinblastine)	97
Gemzar	98
Abraxane (Paclitaxel [Albumin-bound])	98
Arimidex (Anastrozole)	98
Faslodex (Fulvestrant)	98
Fareston	99
Xeloda (Capecitabine)	99
Zoladex (Goserelin Acetate)	99
Ixempra (Ixabepilone)	99
Tykerb (Lapatinib Ditosylate)	99
Abraxane (Paclitaxel [Albumin-bound])	100
Perjeta (Pertuzumab)	100
Ibrance (Palbociclib)	100
Kadcyla (Ado-trastuzumab Emtansine)	100
Halaven (Eribulin Mesylate)	100
Afinitor (Everolimus)	100
Avastin (Bevacizumab)	101
Leuplin (Leuprolide Acetate)	101
Taxotere (Docetaxel)	101

<b>TOPIC</b>	<b>PAGE NO.</b>
Prognosis After Treatment	101
Breast Cancer Treatment Guidelines	102
Prevention	102
<b>CHAPTER 9 WOMEN'S HEALTH DISORDER THERAPEUTICS MARKET ASSESSMENT</b>	<b>104</b>
<b>GLOBAL WOMEN'S HEALTH MARKET</b>	<b>104</b>
<i>FIGURE 18 GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET BY REGION, 2014-2020 (\$ MILLIONS)</i>	104
<i>FIGURE 19 GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET BY DISORDER TYPE, 2014-2020 (\$ MILLIONS)</i>	105
<i>FIGURE 20 GLOBAL MARKET SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET BY DISORDER TYPE, 2015 (%)</i>	106
<i>FIGURE 21 AVERAGE ANNUAL COST OF THERAPY FOR WOMEN'S HEALTH DISORDERS, 2014-2020 (\$)</i>	107
<b>ENDOMETRIOSIS</b>	108
<i>FIGURE 22 GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET BY REGION, 2014-2020 (\$ MILLIONS)</i>	108
<b>MENOPAUSE</b>	109
<i>FIGURE 23 GLOBAL MARKET FOR THERAPEUTICS TO TREAT MENOPAUSE-RELATED CONDITIONS BY REGION, 2014-2020 (\$ MILLIONS)</i>	109
<b>POSTMENOPAUSAL OSTEOPOROSIS</b>	111
<i>FIGURE 24 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS THERAPEUTICS MARKET BY REGION, 2014-2020 (\$ MILLIONS)</i>	111
<b>POLYCYSTIC OVARY SYNDROME</b>	112
<i>FIGURE 25 GLOBAL MARKET FOR POLYCYSTIC OVARY SYNDROME THERAPEUTICS BY REGION, 2014-2020 (\$ MILLIONS)</i>	112
<b>BREAST CANCER</b>	113
<i>FIGURE 26 GLOBAL BREAST CANCER THERAPEUTICS MARKET BY REGION, 2014-2020 (\$ MILLIONS)</i>	114
<b>ANNUAL COST OF THERAPY</b>	114
<i>FIGURE 27 GLOBAL AVERAGE ANNUAL COST OF THERAPY BY DISORDER, 2014-2020 (\$)</i>	115
<b>GENERICS VERSUS BRANDED</b>	116
<i>FIGURE 28 GLOBAL SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET: BRANDED VS. GENERIC, 2015 (%)</i>	116
<b>MARKET GROWTH DRIVERS AND RESTRAINTS</b>	117
Growth Drivers for Menopause-Related Conditions	117
Aging Female Population	117
Growth Restraints for Menopause	117
Low Rate of Prescriptions for Hormone Therapy	117
Availability of Alternative Treatment Options	117
Lack of Safe and Efficacious Drug	118
Growth Drivers for Endometriosis	118
Increasing Awareness	118
Growth Restraints for Endometriosis	118
Poor Diagnosis	118
Absence of Non-hormonal Therapy	119
Growth Drivers for Postmenopausal Osteoporosis	119
Increasing Disease Population	119
Sedentary Lifestyle	120

<b>TOPIC</b>	<b>PAGE NO.</b>
Growth Restraints for Postmenopausal Osteoporosis	120
Poor Diagnosis	120
Growth Drivers for PCOS	120
Growing Treated Population	120
Growth Restraints for PCOS	120
Unavailability of Novel Drugs	120
Growth Drivers for Breast Cancer	121
Increasing Prevalence of Breast Cancer	121
Rising Government Involvement	121
Increasing Funding	121
Ethical Acceptance	121
DNA Vaccines	121
Growth Restraints for Breast Cancer	121
Lack of Awareness	121
High Cost	122
<b>CHAPTER 10 COMPETITION AND MARKET SHARES</b>	<b>124</b>
<i>TABLE 15 LEADING COMPANIES IN THE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, 2015 (\$ MILLIONS/%)</i>	124
<i>FIGURE 29 GLOBAL MARKET SHARES OF LEADING COMPANIES IN WOMEN'S HEALTH THERAPEUTICS INDUSTRY, 2015 (%)</i>	125
<b>CHAPTER 11 MARKET STRATEGY</b>	<b>127</b>
<i>TABLE 16 KEY MERGERS/ACQUISITIONS WITHIN THE WOMEN'S HEALTH MARKET, 2009-JANUARY 2016</i>	127
<b>MERGERS AND ACQUISITIONS</b>	129
TRILLIUM THERAPEUTICS' ACQUISITION OF FLUORINOV PHARMA	129
SHIRE'S ACQUISITION OF DYAX	129
ASTRAZENECA SELLS PCOS CANDIDATE RIGHTS TO MILLENDO THERAPEUTICS	129
PFIZER'S ACQUISITION OF HOSPIRA	129
MEDIVATION'S ACQUISITION OF OF ALL WORLDWIDE RIGHTS TO TALAZOPARIB (BMN 673), A POTENT PARP INHIBITOR, FROM BIOMARIN	130
SHIRE'S ACQUISITION OF NPS PHARMACEUTICALS	130
OPKO HEALTH'S ACQUISITION OF EIRGEN PHARMA	130
ABBVIE'S ACQUISITION OF PHARMACYCLICS	130
ACTAVIS' ACQUISITION OF ALLERGAN	130
NOVARTIS' ACQUISITION OF GSK'S ONCOLOGY DIVISION	130
ENDO INTERNATIONAL'S ACQUISITION OF PAR PHARMACEUTICAL	131
VALEANT'S ACQUISITION OF DENDREON	131
SUN PHARMACEUTICALS' ACQUISITION OF RANBAXY	131
ABBOTT'S ACQUISITION OF VEROPHARM	131
ROCHE'S ACQUISITION OF SERAGON PHARMACEUTICALS	131
BAYER'S ACQUISITION OF ALGETA	131
ENDO INTERNATIONAL'S ACQUISITION OF PALADIN LABS	132
PRESCIENT THERAPEUTICS' ACQUISITION OF AKTIVATE THERAPEUTICS AND PATHWAY ONCOLOGY	132
ACTAVIS' ACQUISITION OF WARNER CHILCOTT	132
AMGEN'S ACQUISITION OF MUSTAFA NEVZAT (MN) PHARMACEUTICALS	132



<b>TOPIC</b>	<b>PAGE NO.</b>
VALEANT PHARMACEUTICALS' ACQUISITION OF INOVA	132
TAKEDA'S ACQUISITION OF NYCOMED	133
TEVA PHARMACEUTICAL'S ACQUISITION OF THERAMEX	133
THERAPEUTICSMD'S ACQUISITION OF VITAMEDMD	133
SANOFI-AVENTIS' ACQUISITION OF BMP SUNSTONE	133
ABBOTT'S ACQUISITION OF SOLVAY PHARMACEUTICALS	134
FERRING PHARMACEUTICALS' ACQUIRED GLOBAL RIGHTS TO LYSTEDA FROM XANODYNE PHARMACEUTICALS	134
BIOSANTE ACQUIRED ELESTRIN ROYALTY FROM AZUR PHARMA	134
TEVA-KOWA PHARMA ACQUIRED MAJORITY STAKE IN TAISHO PHARMACEUTICAL	135
SCIELE PHARMA'S ACQUISITION OF ADDRENEX PHARMACEUTICALS	135
WARNER CHILCOTT'S ACQUISITION OF PROCTER & GAMBLE'S PRESCRIPTION DRUG BUSINESS	135
BIOSANTE PHARMACEUTICALS MERGES WITH CELL GENESYS	136
HISAMITSU PHARMACEUTICAL'S ACQUISITION OF NOVEN PHARMACEUTICALS	136
PFIZER'S ACQUISITION OF WYETH	136
PAR PHARMACEUTICALS' ACQUISITION OF MDRNA'S CALCITONIN ASSETS AND MANUFACTURING FACILITY	136
CHAPTER 12 DRUG PIPELINE ANALYSIS	139
<i>TABLE 17 PIPELINE DRUGS IN WOMEN'S HEALTH</i>	139
DRUGS UNDER DEVELOPMENT	144
PB272 (NERATINIB)	144
Description	144
Safety/Efficacy	145
Clinical Trials	145
ABP 215 (BEVACIZUMAB)	145
Description	145
Clinical Trials	146
AD-RTS-IL-12	146
Description	146
Clinical Trials	146
ABEMACICLIB (LY2835219)	146
Description	146
Clinical Trials	146
ATEZOLIZUMAB	147
Description	147
Clinical Trials	147
BUPARLISIB (BKM120)	147
Description	147
Clinical Trials	147
ALPELISIB (BYL719)	148
Description	148
Clinical Trials	148
CDX-011 (GLEMBATUMUMAB VEDOTIN)	148
Description	148

<b>TOPIC</b>	<b>PAGE NO.</b>
Clinical Trials	148
ENTINOSTAT	148
Description	148
Clinical Trials	149
LEE011 (RIBOCICLIB)	149
Description	149
Clinical Trials	149
LYNPARZA (OLAPARIB)	149
Description	149
Clinical Trials	149
TRASTUZUMAB	150
VELIPARIB (ABT-888)	150
Description	150
Clinical Trials	150
TASELISIB	150
TALAZOPARIB (BMN 673)	151
Description	151
Clinical Trials	151
NK105 (PACLITAXEL)	151
NIRAPARIB	151
Description	151
Clinical Trials	151
JDS-CR-004 (ORAL, PCOS)	152
Description	152
Clinical Trials	152
DIAMEL	152
Description	152
Clinical Trials	152
DLBS-3233; INLACIN	152
MLE4901	153
Description	153
Clinical Trials	153
BAYER- SPRM (BAY 1002670) VILAPRISAN	153
Description	153
Clinical Trials	153
INTRAVAGINAL RING (BAY 98-7196)	153
OBE2109	154
Description	154
Clinical Trials	154
ABALOPARATIDE-SC	154
Description	154
Clinical Trials	154
RAD1901	155
Description	155
Clinical Trials	155
BPS-804	155
Description	155

<b>TOPIC</b>	<b>PAGE NO.</b>
Clinical Trials	155
BA058/ITM-058 (ABALOPARATIDE)	155
CAPSITONIN (CALCITONIN SALMON) AND CAPTHYMONE (PARATHYROID HORMONE)	156
FABLYN (LASOFOXIFENE)	156
PREOB (AUTOLOGOUS OSTEObLAST)	156
Description	156
Clinical Trials	156
SALUBRIN HF	156
TBRIA (CALCITONIN-SALMON [RDNA ORIGIN])	157
Description	157
Clinical Trials	157
TX 12-002-HR (PROGESTERONE)	157
Description	157
Clinical Trials	157
TAK-385 (RELUGOLIX)	157
Description	157
Safety/Efficacy	158
Clinical Trials	158
ELAGOLIX	158
Description	158
Safety/Efficacy	159
Clinical Trials	159
ASP1707	161
Description	161
Clinical Trials	161
PROELLEX (TELAPRISTONE ACETATE) (6 MG AND 12 MG, LOW DOSE ORAL)	161
Description	161
Safety/Efficacy	162
Low Dose Oral Study	162
Vaginal Administration	163
PGL2001 (PGL2)	163
Description	163
Safety/Efficacy	164
Clinical Trials	164
PGL5001 (PGL5) (BENTAMAPIMOD/PROOF OF CONCEPT)	164
Description	164
Clinical Trials	164
KLH-2109	165
Description	165
Clinical Trials	165
AUS-131 (S-EQUOL)	165
Description	165
Safety/Efficacy	165
Clinical Trials	165
MPI-676 AND MPI-674 (FEMATHINA)	166
Description	166
Clinical Trials	166

<b>TOPIC</b>	<b>PAGE NO.</b>
17HSD1 (17-BETA-HYDROXYSTEROID DEHYDROGENASE 1)	167
Description	167
Safety/Efficacy	167
Clinical Trials	168
FEMITRA (ACOLBIFENE + DHEA (ORAL) + GNRH AGONIST) (SUBCUTANEOUS)	168
Description	168
BAY 1026153	168
Description	168
MK-0822 (ODANACATIB)	168
Description	168
Safety and Efficacy	169
Clinical Trials	169
MENERBA	170
Description	170
Safety/Efficacy	170
Clinical Trials	171
SEALA	172
Description	172
Clinical Trials	172
BA058-SC (ABALOPARATIDE)	172
Description	172
Safety/Efficacy	173
Clinical Trials	173
BA058-TD (TRANSDERMAL DELIVERY)	175
Description	175
Safety/Efficacy	175
Clinical Trials	175
RAD1901	176
Description	176
Safety/Efficacy	176
Clinical Trials	176
ZP-PTH (TERIPARATIDE)	177
Description	177
Safety/Efficacy	177
Clinical Trials	177
RECOMBINANT ORAL SALMON CALCITONIN	178
Description	178
Safety/Efficacy	178
Clinical Trials	179
ESN364	179
Description	179
Safety/Efficacy	179
Clinical Trials	179
VAGINORM	180
Description	180
Clinical Trials	180
AZD4901	180

<b>TOPIC</b>	<b>PAGE NO.</b>
Description	180
Clinical Trials	180
<b>ESTRADIOL + TESTOSTERONE GEL</b>	180
Description	180
<b>AMG 785/CDP7851 (ROMOSUZUMAB)</b>	181
Description	181
Safety/Efficacy	181
Clinical Trials	181
<b>TX 12-001HR (17B ESTRADIOL + PROGESTERONE)</b>	182
Description	182
Clinical Trials	182
<b>CHAPTER 13 REGULATORY STRUCTURE</b>	184
<b>UNITED STATES</b>	184
<b>EUROPE</b>	185
<b>REGULATORY PROCEDURES</b>	186
National Authorization Procedure	186
Centralized Procedure	186
Decentralized Procedure	186
Mutual Recognition Procedure	186
<b>JAPAN</b>	186
<b>CHAPTER 14 PRICING AND REIMBURSEMENT</b>	190
<b>UNITED STATES</b>	190
<b>EUROPE</b>	192
<b>JAPAN</b>	193
<b>CHAPTER 15 CONCLUSIONS-OUTLOOK FOR WOMEN'S HEALTH THERAPEUTICS</b>	195
<b>MAJOR DEVELOPMENTS TO INFLUENCE MARKET</b>	195
<b>THERAPEUTIC DEVELOPMENTS</b>	195
<b>DEMOGRAPHIC AND ECONOMIC TRENDS</b>	197
Increasing Aging Population	197
<i>TABLE 18 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2005-2020 (YEARS)</i>	197
<i>FIGURE 30 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2005-2020 (YEARS)</i>	197
<i>TABLE 19 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)</i>	198
<i>FIGURE 31 PROJECTED GLOBAL FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)</i>	198
<i>TABLE 20 PROJECTED U.S. FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)</i>	199
<i>FIGURE 32 PROJECTED U.S. FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)</i>	199
<i>TABLE 21 PROJECTED EUROPEAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)</i>	200
<i>FIGURE 33 PROJECTED EUROPEAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)</i>	200
<i>TABLE 22 PROJECTED JAPAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)</i>	201
<i>FIGURE 34 PROJECTED JAPAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)</i>	201
Income Growth in Developing Markets	202

TOPIC	PAGE NO.
<i>TABLE 23 PROJECTED TRENDS IN PER CAPITA REAL GDP GROWTH BY REGION, 2015-2020 (ANNUAL AVERAGE PERCENTAGE CHANGE)</i>	203
TRENDS IN REIMBURSEMENT	203
FUTURE OUTLOOK	204
CHAPTER 16 COMPANY PROFILES	206
ABBVIE	206
ALLERGAN	206
AMGEN	207
ASAHI KASAI	208
ASTELLAS PHARMA INC.	208
ASTRAZANECA	209
BAYER	210
BIONOVO	210
CELGENE	211
CHUGAI PHARMACEUTICALS	212
DEPOMED INC.	212
EISAI	213
ELI LILLY	213
ENDOCEUTICS	214
FORENDO PHARMA OY	215
GLAXOSMITHKLINE	215
IPSEN SA	216
LES LABORATORIES SERVIER SAS	217
MERCK	217
MOCHIDA PHARMA CO. LTD.	218
MEDITRINA PHARMACEUTICALS INC.	219
NEUROCRINE BIOSCIENCES INC.	219
NOVARTIS AG	220
NOVO NORDISK A/S	221
NOVOGYNE PHARMACEUTICALS	221
OASMIA PHARMACEUTICAL	222
ORION PHARMA LTD.	222
OTSUKA HOLDINGS	222
PALADIN LABS INC.	223
PFIZER INC.	224
PREGLEM SA	225
PUMA BIOTECHNOLOGY	225
ROCHE	226
RADIUS HEALTH INC.	227
REPROS THERAPEUTICS INC.	227
SANOFI	228
TAKEDA PHARMACEUTICAL	228
TARSA THERAPEUTICS INC.	229
TEVA PHARMACEUTICAL INDUSTRIES	229
THERAPEUTICSMD	230
TSUMURA & CO.	231
WARNER CHILCOTT CORP. (SUBSIDIARY OF ACTAVIS)	231

<b>TOPIC</b>	<b>PAGE NO.</b>
ZIOPHARM ONCOLOGY	232
ZOSANO PHARMA INC.	232
CHAPTER 17 INDUSTRY AND PROFESSIONAL ORGANIZATIONS	235
AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR)	235
AMERICAN CANCER SOCIETY	235
AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE (ASRM)	235
AMERICAN SOCIETY OF BREAST SURGEONS	235
AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)	235
ANDROGEN EXCESS AND PCOS SOCIETY	236
ASIA-PACIFIC MENOPAUSE FEDERATION	236
AVON BREAST CANCER CRUSADE	236
BREASTCANCER.ORG	236
ENDOMETRIOSIS ASSOCIATION	236
ENDOMETRIOSIS FOUNDATION OF AMERICA (EFA)	237
ENDOMETRIOSIS.ORG	237
ENDOMETRIOSIS RESEARCH CENTRE (ERC)	237
ENDOMETRIOSIS U.K.	237
EUROPEAN CANCER OBSERVATORY	238
EUROPEAN ENDOMETRIOSIS LEAGUE (EEL)	238
EUROPEAN MENOPAUSE AND ANDROPAUSE SOCIETY (EMAS)	238
EUROPEAN SOCIETY OF HUMAN REPRODUCTION AND EMBRYOLOGY (ESHRE)	239
FOOD AND DRUG ADMINISTRATION (FDA)	239
GLOBAL CANCER FOUNDATION	239
HORMONE FOUNDATION	239
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER	240
INTERNATIONAL FEDERATION OF PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS (IFPMA)	240
INTERNATIONAL MENOPAUSE SOCIETY (IMS)	240
INTERNATIONAL OSTEOPOROSIS FOUNDATION (IOF)	240
JAPAN ENDOMETRIOSIS ASSOCIATION (JEMA)	241
JAPAN SOCIETY FOR MENOPAUSE AND WOMEN'S HEALTH	241
JAPANESE BREAST CANCER SOCIETY	241
NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION (NCBI)	241
NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN)	242
NATIONAL INSTITUTE ON AGING (NIA)	242
NORTH AMERICAN MENOPAUSE SOCIETY (NAMS)	242
NATIONAL OSTEOPOROSIS FOUNDATION (NOF)	243
NATIONAL WOMEN'S HEALTH INFORMATION CENTER (NWHIC)	243
PCOSUPPORT	243
WORLD CANCER RESEARCH FUND INTERNATIONAL	243
WORLD ENDOMETRIOSIS RESEARCH FOUNDATION (WERF)	244
WORLDWIDE CANCER RESEARCH	244
CHAPTER 18 ABBREVIATIONS	246

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)	7
TABLE 1 GLOBAL GENERAL FEMALE POPULATION VS POPULATION SUFFERING FROM A WOMEN'S DISORDER, THROUGH 2020 (MILLIONS)	11
TABLE 2 GLOBAL PREVALENCE OF MENOPAUSE-RELATED CONDITIONS BY REGION, THROUGH 2020 (MILLIONS)	22
TABLE 3 COMMONLY PRESCRIBED DRUGS USED TO TREAT THE SYMPTOMS OF MENOPAUSE	27
TABLE 4 GLOBAL PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS BY REGION, THROUGH 2020 (MILLIONS)	35
TABLE 5 COMMONLY PRESCRIBED DRUGS USED TO TREAT POSTMENOPAUSAL OSTEOPOROSIS	44
TABLE 6 PREVALENCE OF ENDOMETRIOSIS BY REGION, THROUGH 2020 (MILLIONS)	59
TABLE 7 DRUGS COMMONLY USED TO TREAT ENDOMETRIOSIS	66
TABLE 8 PREVALENCE OF POLYCYSTIC OVARY SYNDROME BY REGION, THROUGH 2020 (MILLIONS)	72
TABLE 9 COMMONLY PRESCRIBED GENERIC DRUGS FOR THE TREATMENT OF POLYCYSTIC OVARY SYNDROME	77
TABLE 10 TNM CLASSIFICATIONS OF BREAST CANCERS	86
TABLE 11 FIVE-YEAR SURVIVAL RATE BASED ON STAGE OF BREAST CANCER FOR WOMEN IN THE U.S, 2015 (%)	87
TABLE 12 PREVALENCE OF BREAST CANCER BY REGION, THROUGH 2020 (MILLIONS)	87
TABLE 13 TYPES OF HORMONE THERAPY FOR BREAST CANCER	93
TABLE 14 DRUGS COMMONLY USED TO TREAT BREAST CANCER	94
TABLE 15 LEADING COMPANIES IN THE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, 2015 (\$ MILLIONS/%)	124
TABLE 16 KEY MERGERS/ACQUISITIONS WITHIN THE WOMEN'S HEALTH MARKET, 2009-JANUARY 2016	127
TABLE 17 PIPELINE DRUGS IN WOMEN'S HEALTH	139
TABLE 18 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2005-2020 (YEARS)	197
TABLE 19 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)	198
TABLE 20 PROJECTED U.S. FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)	199
TABLE 21 PROJECTED EUROPEAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)	200
TABLE 22 PROJECTED JAPAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)	201
TABLE 23 PROJECTED TRENDS IN PER CAPITA REAL GDP GROWTH BY REGION, 2015-2020 (ANNUAL AVERAGE PERCENTAGE CHANGE)	203



**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, 2014-2020 (\$ MILLIONS)	7
FIGURE 1 DISTRIBUTION OF GLOBAL POPULATION SUFFERING FROM A WOMEN'S DISORDER BY TYPE, 2015 (% OF TOTAL GENERAL FEMALE POPULATION)	12
FIGURE 2 FEMALE LIKELIHOOD OF BECOMING PREGNANT VERSUS INFERTILITY AS AGE PROGRESSES, 2015 (%)	14
FIGURE 3 GLOBAL PREVALENCE OF MENOPAUSE-RELATED CONDITIONS BY REGION, 2014-2020 (MILLIONS)	22
FIGURE 4 GLOBAL POPULATION OF FEMALES SUFFERING FROM MENOPAUSE-RELATED CONDITIONS VS THE GENERAL FEMALE POPULATION, 2014-2020 (MILLIONS)	23
FIGURE 5 GLOBAL DISTRIBUTION OF FEMALES SUFFERING FROM MENOPAUSE-RELATED CONDITIONS BY REGION, 2015 (% OF GENERAL FEMALE POPULATION)	24
FIGURE 6 GLOBAL PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS BY REGION, 2014-2020 (MILLIONS)	36
FIGURE 7 GLOBAL POPULATION OF FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS VS THE OVERALL FEMALE POPULATION, 2014-2020 (MILLIONS)	36
FIGURE 8 GLOBAL DISTRIBUTION OF FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS BY GEOGRAPHIC REGION, 2015 (% OF FEMALE POPULATION)	37
FIGURE 9 PREVALENCE OF ENDOMETRIOSIS BY REGION, 2014-2020 (MILLIONS)	59
FIGURE 10 GLOBAL ENDOMETRIOSIS POPULATION VS OVERALL FEMALE POPULATION, 2014-2020 (MILLIONS)	60
FIGURE 11 GLOBAL DISTRIBUTION OF ENDOMETRIOSIS POPULATION BY REGION, 2015 (% OF FEMALE POPULATION)	61
FIGURE 12 PREVALENCE OF POLYCYSTIC OVARY SYNDROME BY REGION, 2014-2020 (MILLIONS)	73
FIGURE 13 GLOBAL POLYCYSTIC OVARY SYNDROME DISEASE POPULATION VS FEMALE POPULATION, 2014-2020 (MILLIONS)	73
FIGURE 14 GLOBAL DISTRIBUTION OF POLYCYSTIC OVARY SYNDROME POPULATION BY REGION, 2015 (% OF FEMALE POPULATION)	74
FIGURE 15 PREVALENCE OF BREAST CANCER BY REGION, 2014-2020 (MILLIONS)	88
FIGURE 16 GLOBAL BREAST CANCER POPULATION VS OVERALL FEMALE POPULATION, 2014-2020 (MILLIONS)	88
FIGURE 17 GLOBAL DISTRIBUTION OF BREAST CANCER POPULATION BY REGION, 2015 (% OF FEMALE POPULATION)	89
FIGURE 18 GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET BY REGION, 2014-2020 (\$ MILLIONS)	104
FIGURE 19 GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET BY DISORDER TYPE, 2014-2020 (\$ MILLIONS)	105
FIGURE 20 GLOBAL MARKET SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET BY DISORDER TYPE, 2015 (%)	106
FIGURE 21 AVERAGE ANNUAL COST OF THERAPY FOR WOMEN'S HEALTH DISORDERS, 2014-2020 (\$)	107
FIGURE 22 GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET BY REGION, 2014-2020 (\$ MILLIONS)	108
FIGURE 23 GLOBAL MARKET FOR THERAPEUTICS TO TREAT MENOPAUSE-RELATED CONDITIONS BY REGION, 2014-2020 (\$ MILLIONS)	109
FIGURE 24 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS THERAPEUTICS MARKET BY REGION, 2014-2020 (\$ MILLIONS)	111

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 25 GLOBAL MARKET FOR POLYCYSTIC OVARY SYNDROME THERAPEUTICS BY REGION, 2014-2020 (\$ MILLIONS)	112
FIGURE 26 GLOBAL BREAST CANCER THERAPEUTICS MARKET BY REGION, 2014-2020 (\$ MILLIONS)	114
FIGURE 27 GLOBAL AVERAGE ANNUAL COST OF THERAPY BY DISORDER, 2014-2020 (\$)	115
FIGURE 28 GLOBAL SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET: BRANDED VS. GENERIC, 2015 (%)	116
FIGURE 29 GLOBAL MARKET SHARES OF LEADING COMPANIES IN WOMEN'S HEALTH THERAPEUTICS INDUSTRY, 2015 (%)	125
FIGURE 30 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2005-2020 (YEARS)	197
FIGURE 31 PROJECTED GLOBAL FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)	198
FIGURE 32 PROJECTED U.S. FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)	199
FIGURE 33 PROJECTED EUROPEAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)	200
FIGURE 34 PROJECTED JAPAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)	201